Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Common Variable Immunodeficiency
Conditions
Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Autosomal Recessive Agammaglobulinemia
Trial Timeline
Sep 1, 2007 → Aug 1, 2009
NCT ID
NCT00542997About Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) is a phase 3 stage product being developed by CSL for Common Variable Immunodeficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00542997. Target conditions include Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Autosomal Recessive Agammaglobulinemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00542997 | Phase 3 | Completed |
Competing Products
20 competing products in Common Variable Immunodeficiency